SEC Form SC 13D/A filed by Kindred Biosciences, Inc. (Amendment)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

KINDRED BIOSCIENCES INC.

(Name of Issuer)

Common Stock, par value $0.0001

(Title of Class of Securities)

494577109

(CUSIP Number of Class of Securities)

Alec N. Litowitz

Magnetar Capital LLC 

1603 Orrington Ave.

Evanston, Illinois 60201 

(847) 905-4400

(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)

June 28, 2020

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a Statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this Schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7(b) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 

SCHEDULE 13D

This Amendment No. 1 (the “Amendment”) relates to the Statement of Beneficial Ownership on Schedule 13D filed jointly by Magnetar Financial LLC, a Delaware limited liability company (“Magnetar Financial”), Magnetar Capital Partners LP, a Delaware limited partnership (“Magnetar Capital Partners”), Supernova Management LLC, a Delaware limited liability company (“Supernova Management”), and Alec N. Litowitz (“Mr. Litowitz”) (collectively, the “Reporting Persons”) with the SEC on June 25, 2021, (as amended by this Amendment, the “Schedule 13D”).

Except as set forth below, all Items of the Schedule 13D remain unchanged. All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D.

Item 3 of the Schedule 13D is hereby amended to add the following information for updating:

The aggregate amount of funds used by the Reporting Persons in purchasing the 479,842 Shares reported herein on behalf of the Funds have come directly from the assets of the Funds, which may at any given time, have included margin loans made by brokerage firms in the ordinary course of business. The aggregate amount of funds used by the Reporting Persons in purchasing the Shares on behalf of the Funds was $4,399,437.20 (excluding commissions and other execution-related costs).

Item 4 of the Schedule 13D is hereby amended to add the following information for updating:

Since the filing of the 13D with the SEC on June 25, 2021, the Reporting Persons purchased 479,842 between June 25, 2021 and June 28, 2021 reported herein which consists of (i) 271,278 Shares purchased for the benefit of PRA Master Fund, (ii) 151,109 Shares purchased for the benefit of Constellation Fund; and (iii) 57,455 Shares purchased for the benefit of Systematic Master Fund

Item 5 of the Schedule 13D is hereby amended to add the following information for updating:

(a)            As of the close of business June 28, 2021, each of the Reporting Persons may have been deemed to have beneficial ownership of 3,421,425 Shares, which consisted of (i) 1,934,240 Shares held for the benefit of PRA Master Fund, (ii) 1,077,438 Shares held for the benefit of Constellation Fund; and (iii) 409,747 Shares held for the benefit of Systematic Master Fund, and all such Shares represented beneficial ownership of approximately 7.55% of the Shares.

(b)            As of the close of business June 28, 2021, each of the Reporting Persons may have been deemed to share the power to vote and direct the disposition of 3,421,425 Shares, which consisted of (i) 1,934,240 Shares held for the benefit of PRA Master Fund, (ii) 1,077,438 Shares held for the benefit of Constellation Fund; and (iii) 409,747 Shares held for the benefit of Systematic Master Fund, and all such Shares represented beneficial ownership of approximately 7.55% of the Shares.

(c)            Except as set forth on Schedule A attached hereto, the Funds had no transactions since the filing of the Schedule 13D on June 25, 2021 through the close of business on June 28, 2021, except for the transactions set forth on Schedule A. All of the transactions set forth on Schedule A attached hereto were effected as part of the risk arbitrage strategy of Magnetar Financial for the accounts of each of the Funds. The transactions in the Shares set forth on Schedule A were effected in open market transactions on NASDAQ and various other trading markets.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

SCHEDULE A

Funds

(1)Excludes commissions and other execution-related costs.

(2) Upon request by the staff of the Securities and Exchange Commission, full information regarding the number of shares bought or sold (as the case may be) at each separate price will be provided.

(3) Reflects a weighted average purchase price of $9.16842per share, at prices ranging from $9.13 to $9.20 per share.

(4) Reflects a weighted average purchase price of $9.16955 per share, at prices ranging from $9.15 to $9.20 per share.